HF/Transplantation News

Implicity announced it received 510(k) clearance from the FDA for its new AI algorithm to assess risk for future HF events from data gathered from various cardiac implantable electronic devices.

No athlete with a positive test for genetic heart disease but a negligible clinical phenotype had a genetic heart disease-associated death or cardiac event in more than 1,500 person-years of follow-up, researchers reported.

Abbott/Thoratec Corp. announced the recall of its left ventricular assist device implant kit due to complaints of blood leakage or air entering the seal interface between the LVAD inflow cannula and the apical cuff.

Moderate to vigorous aerobic and resistance exercise may improve vascular function among cancer survivors, according to findings presented at American Association for Cancer Research Annual Meeting.

In patients with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten improved exercise capacity and quality of life compared with placebo, according to the results of the SEQUOIA-HCM trial.

In patients with the obesity phenotype of HF with preserved ejection, semaglutide 2.4 mg improved HF-related symptoms and physical limitations vs. placebo regardless of diuretic use, according to new data from the STEP-HFpEF trials.

A new guideline on hypertrophic cardiomyopathy endorses the use of cardiac myosin inhibitors for certain patients with obstructive HCM and encourages exercise in all patients with HCM.

BOSTON — A “laundry list of new trials” in cardiovascular medicine has led to “a decided portfolio of new ways of thinking, new interventions and a new potential to modify the natural history of CVD,” an expert said.

Researchers have created a novel tool that predicts a person’s risk for cardiovascular complications after bone marrow transplantation.

ATLANTA — Among patients with lower socioeconomic status, interventions based on case management and financial incentives improved attendance at cardiac rehabilitation sessions, according to the results of the HeLP trial.